SCHEMBL4172164

SCHEMBL4172164

CCn1cc(C(=O)O)c(=O)c2ccc(Cl)nc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.74
KMT2A Q03164 5/20 0.74
MEN1 O00255 4/20 0.74
ABCC4 O15439 1/20 0.74
PKM P14618 1/20 0.74
PTGS1 P23219 1/20 0.74
TSHR P16473 4/20 0.65
HIF1A Q16665 1/20 0.65
HSD17B10 Q99714 3/20 0.56
CYP1A2 P05177 2/20 0.56
KDM4E B2RXH2 2/20 0.56
NFKB1 P19838 1/20 0.56
BLM P54132 1/20 0.56
CASP1 P29466 1/20 0.54
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9805935 0.86 LMNA (0.74) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL7878858 0.85 KMT2A (1.00) LMNAKMT2AMEN1ABCC4PKM
SCHEMBL11791745 0.85 LMNA (0.76) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL21736 0.85 KMT2A (1.00) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL29367723 0.85 KMT2A (1.00) LMNAKMT2AMEN1ABCC4PKM
SCHEMBL8703572 0.85 ALDH1A1 (0.62) LMNAKMT2AMEN1ABCC4PKM
SCHEMBL10278384 0.84 LMNA (0.74) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL950987 0.84 KMT2A (0.97) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL4766415 0.84 KMT2A (0.97) LMNAKMT2AMEN1ABCC4PKM
Nalidixic Acid SCHEMBL27256972 0.84 KMT2A (0.97) LMNAKMT2AMEN1ABCC4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776431-B1 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2016-05-04 EP disclosed
US-9079922-B2 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives ACTELION PHARMACEUTICALS LTD (CH) 2015-07-14 US disclosed
US-20150051188-A1 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-02-19 US disclosed
EP-2776431-A1 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2014-09-17 EP disclosed
WO-2013068948-A1 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-05-16 WO disclosed
US-20090062218-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-03-05 US disclosed
US-4017622-A BACTERICIDES DAINIPPON PHARMACEUTICAL CO., LTD. (JA) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051188-A1 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES OXA1L, PYM1, MRPL21 LMNA 1198/4885KMT2A 1930/4885MEN1 538/4885
US-20090062218-A1 MACROLONE COMPOUNDS CYP51A1, MRPL21, MYD88 LMNA 1055/4885KMT2A 3931/4885MEN1 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.